Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Safety in Young Adults (18 to 29): What the Evidence Actually Shows

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA status / No FDA-approved drug contains GHK-Cu [1]
  • Topical products / Sold as cosmetics without FDA approval [2]
  • Compounded injectable / Not approved; FDA flags immunogenicity risk [3]
  • Objective results / No benefit over control for redness, wrinkles or ulcer size [4][5]
  • Patient-rated result / One 13-patient trial favored GHK-Cu for overall skin quality (P=.04) [4]

Is any GHK-Cu product FDA-approved?

No. No FDA-approved drug is known to contain GHK-Cu [1]. Topical copper peptide serums and creams are sold as cosmetics, and cosmetics and cosmetic ingredients other than color additives do not need FDA approval before sale [2]. A topical product that claims to treat disease or change the body's structure or function is legally a drug [2]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved [2].

What do the human trials show?

The two randomized human trials we found are small topical studies: 13 patients after CO2 laser resurfacing and 86 patients with venous stasis ulcers [4][5].

In the 13-patient trial, computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality; a patient questionnaire showed a significant difference in overall skin quality favoring GHK-Cu (P=.04) [4].

In the 86-patient venous ulcer trial, a 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo for ulcer size, while silver sulfadiazine 1% reduced ulcer size [5].

A 2026 systematic review of 64 records concluded that the human literature is thin and fragmented, and that most randomized trials are small and use facial cosmetic creams [6].

What does FDA say about compounded injectable GHK-Cu?

Both trials used topical creams, not injections [4][5]. FDA states: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3].

What is the practical answer for someone 18 to 29?

The only human randomized trials we found used topical creams, and there are two small trials with mixed results [4][5][6]. FDA says human safety data for compounded injectable GHK-Cu are limited and flags a potential immunogenicity risk [3]. No GHK-Cu product is FDA-approved, and there is no FDA-approved GHK-Cu dose [1][2].

A copper peptide cream is a topical product, not an injectable GHK-Cu product.

Frequently asked questions

Is GHK-Cu safe for adults in their 20s?
We found no GHK-Cu trial reporting results specifically for adults aged 18 to 29. The safety of GHK-Cu in this age group has not been established, and we found no GHK-Cu trial reporting results specifically for adults aged 18 to 29. The randomized trials we found are small and topical; objective measures showed no benefit over control, and one 13-patient questionnaire favored GHK-Cu (P=.04) [4][5]. No GHK-Cu product is FDA-approved [1].
Is GHK-Cu FDA-approved?
No. No FDA-approved drug is known to contain GHK-Cu [1]. Topical copper peptide products are sold as cosmetics without FDA approval [2], and injectable GHK-Cu is not FDA-approved [2].
What does FDA say about compounded injectable GHK-Cu?
FDA says compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to aggregation and peptide-related impurities, and that there are limited data in humans to inform safety [3]. Injectable GHK-Cu is not FDA-approved [2].
Do the GHK-Cu trials show a benefit?
The results are mixed. In 13 patients after CO2 laser resurfacing, objective measures found no significant difference, while a patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [4]. In 86 patients with venous ulcers, a 0.4% tripeptide copper complex cream was no different from placebo for ulcer size [5].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  4. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  5. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  6. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
Evidence overview for GHK-Cu Safety in Young Adults (18 to 29): What the Evidence Actually Shows